Hemi-gland focal low dose rate prostate brachytherapy: An analysis of dosimetric outcomes

详细信息    查看全文

• 作者：Robert Laing ; ^{robertlaing@nhs.net} ; Adrian Franklin ; Jennifer Uribe ; Alex Horton ; Santiago Uribe-Lewis ; Stephen Langley
• 关键词：4D brachytherapy ; Prostate cancer ; Focal ; Dosimetry
• 刊名：Radiotherapy and Oncology
• 出版年：2016
• 出版时间：November 2016
• 年：2016
• 卷：121
• 期：2
• 页码：310-315
• 全文大小：869 K
• 卷排序：121

文摘

Advances in magnetic resonance imaging (MRI) and prostate sampling enable early identification of men with low to intermediate risk prostate cancer who are candidates for focal therapies that minimise side effects. We report dosimetry data from a pilot study evaluating the effectiveness of hemi-gland low dose rate (HG-LDR) brachytherapy as a focal therapy approach to control unilateral localised disease.Material and methodsTwenty-two men underwent HG-LDR brachytherapy. Multi parametric MRI and transperineal template mapping biopsies were used to identify low volume unilateral disease. Whole gland therapy controls (n = 120) were retrospectively obtained. All implants were performed with 4D Brachytherapy.ResultsIntraoperative and postimplant dosimetry complied with established brachytherapy parameters. Mean (standard deviation) postoperative D90 for the target hemi-gland was 153.8 (11.3) Gy compared to 47.5 (12.7) Gy for the contralateral hemi-gland (P < 0.001). Mean postoperative V100% was 93.1 (3.9) and 24.6 (10.5) for the target and contralateral hemi-glands respectively (P < 0.001). Urethra D30 was 150.4 (19.8) Gy and 174.2 (15.0) Gy for hemi-gland and whole gland implants respectively (P < 0.001). Significantly reduced dose was also observed for rectum and neurovascular bundles.ConclusionsHG-LDR focal brachytherapy is feasible with significant reduction in dose to the contralateral hemi-gland and organs at risk.